Dynavax Technologies (NASDAQ:DVAX) Shares Pass Above 200 Day Moving Average – Here’s What Happened

Dynavax Technologies Co. (NASDAQ:DVAX)’s stock price crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $11.62 and traded as high as $12.87. Dynavax Technologies shares last traded at $12.62, with a volume of 5,449,688 shares changing hands.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and issued a $29.00 price objective on shares of Dynavax Technologies in a report on Friday, November 8th.

Dynavax Technologies Stock Up 0.1 %

The company’s fifty day simple moving average is $12.74 and its 200 day simple moving average is $11.63. The company has a quick ratio of 12.34, a current ratio of 13.23 and a debt-to-equity ratio of 0.33. The firm has a market capitalization of $1.66 billion, a PE ratio of 97.16 and a beta of 1.34.

Institutional Trading of Dynavax Technologies

A number of hedge funds have recently modified their holdings of DVAX. Nordea Investment Management AB lifted its position in Dynavax Technologies by 42.7% during the 4th quarter. Nordea Investment Management AB now owns 777,816 shares of the biopharmaceutical company’s stock valued at $10,034,000 after acquiring an additional 232,690 shares during the period. GAMMA Investing LLC lifted its holdings in shares of Dynavax Technologies by 55.1% during the fourth quarter. GAMMA Investing LLC now owns 4,102 shares of the biopharmaceutical company’s stock valued at $52,000 after purchasing an additional 1,457 shares during the last quarter. Franklin Resources Inc. lifted its holdings in shares of Dynavax Technologies by 5.7% during the third quarter. Franklin Resources Inc. now owns 82,415 shares of the biopharmaceutical company’s stock valued at $862,000 after purchasing an additional 4,459 shares during the last quarter. Wilmington Savings Fund Society FSB purchased a new stake in shares of Dynavax Technologies in the 3rd quarter worth approximately $89,000. Finally, Sanctuary Advisors LLC increased its position in Dynavax Technologies by 9.1% during the 3rd quarter. Sanctuary Advisors LLC now owns 17,727 shares of the biopharmaceutical company’s stock valued at $197,000 after buying an additional 1,484 shares in the last quarter. Institutional investors own 96.96% of the company’s stock.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.